chartexchange

RGNX
REGENXBIO Inc.
stockNASDAQ

At CloseNov 18, 2026 3:59:58 PM EST
7.27USD+0.414%(+0.03)701,901
Pre-marketNov 18, 2026 9:28:30 AM EST
7.25USD+0.138%(+0.01)
After-hoursNov 18, 2026 4:59:30 PM EST
7.27USD0.000%(0.00)
Loading…
Loading…
481.04M
Healthcare
Biotechnology
CEO
Kenneth Mills
HQ
Rockville, MD, USA
Previous Close
$7.24
Beta
1.85
52-Week High
$16.19 2026-01-22
52-Week Low
$5.46 2026-05-18
SMA 50
$7.56
SMA 200
$8.82
Avg. Vol 10D
1.25M
Avg. Vol 30D
1.30M
Avg. Vol 90D
1.41M
Relative Vol
0.54
57.31M
10,179,714
0.2800%
4,000,000
RGNX Profile

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.

RGNX Performance
PeriodPriceDateChangeBeta
1W8.032026-11-12-9.40%1.151
1M7.152026-10-19+1.75%1.883
3M12.022026-08-19-39.48%1.927
6M5.662026-05-19+28.53%1.843
1Y10.932025-11-19-33.44%1.851
2Y9.562024-11-19-23.90%—
5Y33.512021-11-19-78.29%1.510
RGNX Stock Summary

REGENXBIO Inc. (NASDAQ:RGNX) stock price today is $7.28, and today's volume is 701,901. RGNX is up 0.483% today. The 30 day average volume is 1.30M. RGNX market cap is $481.04M with 66.12M shares outstanding.